Richard L. Lindstrom MD - 20 Feb 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Director
Signature
/s/ Todd Anderman, Attorney-in-Fact for Richard L. Lindstrom, M.D.
Issuer symbol
OCUL
Transactions as of
20 Feb 2026
Net transactions value
+$461,354
Form type
4
Filing time
24 Feb 2026, 18:13:03 UTC
Previous filing
13 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LINDSTROM RICHARD L MD Director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD /s/ Todd Anderman, Attorney-in-Fact for Richard L. Lindstrom, M.D. 24 Feb 2026 0001242177

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Purchase $461,354 +60,229 +32% $7.66 246,933 20 Feb 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.64 to $7.69, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2 Includes 43,559 shares transferred from the Lindstrom Family No 2 Limited Partnership to the reporting person.